Affordable Access

Publisher Website

Cladribine in the treatment of hairy-cell leukaemia

Authors
Journal
Best Practice & Research Clinical Haematology
1521-6926
Publisher
Elsevier
Publication Date
Volume
16
Issue
1
Identifiers
DOI: 10.1016/s1521-6926(02)00089-0
Keywords
  • Cladribine
  • 2-Chlorodeoxyadenosine
  • Hairy-Cell Leukaemia
  • Purine Analogue
Disciplines
  • Chemistry
  • Medicine

Abstract

Abstract Cladribine, a purine nucleoside analogue, is a safe and effective treatment for patients with hairy-cell leukaemia. It is administered at a dose of 0.09 mg/kg daily as a continuous intravenous infusion over 7 days. This chapter discusses the history, rationale, chemical structure and mechanism of action of cladribine. The indications for therapy and guidelines for clinical usage are reviewed. The response of hairy-cell leukaemia to cladribine, the acute and chronic complications and the risk for second malignancies are summarized. The chapter concludes with a section on salvage therapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Cladribine in the treatment of hairy-cell leukaemi...

on Best practice & research. Clin... March 2003

Hairy-cell leukaemia: first-line treatment with cl...

on Prescrire international August 2006

Systemic vasculitis complicating hairy cell leukae...

on Clinical and laboratory haemat... August 2002

Low-dose cladribine for symptomatic hairy cell leu...

on British Journal of Haematology March 1995
More articles like this..